The early introduction of disease modifying therapy can not only be considered today as a factor of good prognosis, but can even help to better identify some factors or initial prognostic variables.
An example of this is pointed out by Mottonen et al in a study on prognostic factors at the onset of the disease, which includes 142 patients with initial RA followed for up to 6 years and treated with the swatooth strategy Hondrocream; in this study, patients with positive rheumatoid factor at baseline did not have a greater radiological progression.
No comments:
Post a Comment